Dravet syndrome and other developmental epileptic encephalopathies are rare but devastating conditions that cause a host of ...

More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.

Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.

Experts discuss the current research on the use of digital therapeutics for managing chronic pain in rheumatic disease.

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company with a market capitalization of $156.6 million, is at a pivotal juncture in its development of programmed cellular ...

The 2019 EULAR/ACR systemic lupus erythematosus classification criteria ... for mortality included variables such as age, sex, and clinical factors (eg, thrombocytopenia, neuropsychiatric ...

HealthDay News — In clinical practice guidelines jointly issued by the U.S. Department of Veterans Affairs and U.S. Department of Defense and published online Jan. 21 in the Annals of Internal ...

Greater attention to geriatric assessment, including screening for dementia, in older adults with SLE may be warranted in clinical settings and requires further investigation. Over a follow-up ...